Abstract
Objectives
To investigate the expression of β3-adrenoceptors in rats with chronic heart failure, and to explore the effect of β-blockers on β3-adrenoceptor expression.
Materials and methods
Thirty-two male Wistar rats were divided into Sham (n = 10) and heart failure (n = 22) groups. The heart failure group was treated with normal saline (Heart Failure Control, n = 6), Metoprolol (n = 8) or Carvedilol (n = 8) for 3 months.
Results
The left ventricular end systolic pressure (LVESP) and the absolute values of maximal rate of rise and fall of left ventricular pressure (±dP/dt max) in the heart failure group were lower than in the Sham group (P < 0.01), whereas the left ventricular end diastolic pressure (LVEDP) was higher (P < 0.01). The LVESP and dP/dtmax in the Carvedilol group were higher than the Metoprolol group whereas LVEDP was lower (P < 0.01). The left ventricular mass index (LVMI) in the Carvedilol group was less than the Metoprolol and Heart Failure Control groups (P < 0.01). The level of β3-adrenoceptor expression in the study groups was significantly higher than the Sham group (P < 0.01). β3-adrenoceptor expression in the Carvedilol group was lower than the Heart Failure Control and Metoprolol groups (P < 0.01).
Conclusion
β3-adrenoceptor expression is increased in the failing ventricles in rats. Carvedilol is more effective than Metoprolol for improving the hemodynamics and in attenuating ventricular remodeling after heart failure. Carvedilol, rather than Metoprolol, diminishes β3-adrenoceptor expression in the failing ventricles.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure. Circ Res 2003;93:896–906.
Morimoto A, Hasegawa H, Cheng GJ, Little WC, Cheng CP. Endogenous β3-adrenoreceptor activation contributes to the left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol, Heart Circ Physiol 2004;286:H2425–33.
Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of β3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649–55.
Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay T, Altan VM. The effect of diabetes on expression of β1-, β2- and β3-adrenoceptors in rat hearts. Diabetes 2001;50:455–61.
Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional β3-adrenergic receptor in the failing canine myocardium. Circ Res 2001;89:599–606.
Tavernier G, Toumaniantz G, Erfanian M, Heymann MF, Laurent K, Langin D, et al. Beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 2003;59:288–96.
Mercadier JJ, Lompre AM, Wisneusky C, Samuel JL, Bercovici J, Swynghedauw B, et al. Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res 1981;49:525–32.
Pott C, Brixius K, Bloch W, Ziskoven C, Napp A, Schwinger RH. β3-adrenergic stimulation in the human heart: signal transduction, functional implications and therapeutic perspectives. Pharmizie 2006;61:255–60.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet 2003; 362:7–13.
Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Bohm M. Binding properties of β-blockers at recombinant β1-, β2-, and β3-adrenoceptors. J Cardiovasc Pharmacol 2000;36:466–71.
Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KNK. Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedebergs Arch Pharmakol 2004;369:151–9.
Coats AJ. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging 2006;23:93–9.
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25.
Lombardo RM, Reina C, Abrignani MG, Rizzo PA, Braschi A, De Castro S. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 2006;6:259–63.
Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Cas LD. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546–51.
Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000;36:76–81.
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819–23.
Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-Adrenergic signaling in heart failure? Circ Res 2003;93:896–906.
Acknowledgement
This study was supported by a Medical, Pharmaceutical and Health Scientific Research Grant from Guangzhou City.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, Q., Wu, TG., Jiang, ZF. et al. Effect of β-Blockers on β3-Adrenoceptor Expression in Chronic Heart Failure. Cardiovasc Drugs Ther 21, 85–90 (2007). https://doi.org/10.1007/s10557-007-6016-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-007-6016-4